Hoplodactylus delcourtiis a presumably extinct species of diplodactylid gecko known only from a single specimen of unknown provenance. It is by far the largest known gekkotan, approximately 50% longer than the next largest-known species. It has been considered a member of the New Zealand endemic genusHoplodactylusbased on external morphological features including shared toe pad structure. We obtained DNA from a bone sample of the only known specimen to generate high-throughput sequence data suitable for phylogenetic analysis of its evolutionary history. Complementary sequence data were obtained from a broad sample of diplodactylid geckos. Our results indicate that the species is not most closely related to extantHoplodactylusor any other New Zealand gecko. Instead, it is a member of a clade whose living species are endemic to New Caledonia. Phylogenetic comparative analyses indicate that the New Caledonian diplodactylid clade has evolved significantly more disparate body sizes than either the Australian or New Zealand clades. Toe pad structure has changed repeatedly across diplodactylids, including multiple times in the New Caledonia clade, partially explaining the convergence in form betweenH. delcourtiand New ZealandHoplodactylus. Based on the phylogenetic results, we placeH. delcourtiin a new genus.

Cachexia is a muscle-wasting syndrome that has a 50% overall prevalence across all cancers and is known to affect both survival and quality of life. However, its measurement, classification, and impact in individuals with primary brain tumors is unclear. Now, evidence is emerging that cachexia has a direct effect on both clinical and physical function outcomes for individuals with glioblastoma multiforme (GBM). Herein, we outline a standardized approach to the diagnosis of cachexia in the GBM population, incorporating several available clinical tools to ensure the link between clinical prognosis and quality of life.